- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2012-05-09 20:25:11
- Reporting Period:
- Filing Date:
- Accepted Time:
- 2012-05-09 19:25:11
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|850693||Allergan Inc||AGN||Pharmaceutical Preparations (2834)||951622442|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1532133||J. David Endicott||2525 Dupont Drive |
Irvine CA 92612
|Cvp And President, Agn Med||No||Yes||No||No|
Reported Non-Derivative Transactions
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
Reported Derivative Transactions
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Employee Stock Option (Right to Buy)||Disposition||2012-05-07||15,000||$0.00||15,000||$40.16|
|Common Stock||Employee Stock Option (Right to Buy)||Disposition||2012-05-07||12,500||$0.00||12,500||$59.13|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
Reported Non-Derivative Holdings
|Sec. Name||Remaning Holdings||Nature of Ownership||Explanation|
|Common Stock||643||Indirect||By 401(k) Trust|
|Common Stock||3,108||Indirect||by ESOP Trust|
- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $93.62 to $94.10, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- Shares allocated to reporting person's SIP account as of reporting date.
- Shares allocated to the reporting person's ESOP account as of reporting date.
- The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options under this award are reported in this filing.
- The option became exercisable in four equal annual installments beginning February 22, 2011. The remaining outstanding options under this award are reported in this filing.